Another study reported a cell line-specific, differential activation of JNK following treatment of two oral squamous cell carcinoma (OSCC) lines with TRAIL, another ligand known to activate the TNFR superfamily [39]. This evidence concerns the gene MAPK8 and oral cavity squamous cell carcinoma.